Seattle Genetics has dosed the first patient in the innovaTV 204 trial, a Phase ll study examining the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for treating patients with recurrent and/or metastatic cervical cancer.

The global, multicentre, single arm trial will include around 100 patients with recurrent and/or metastatic cervical cancer who progressed on or relapsed after treatment with platinum-based chemotherapy used alone or in combination with bevacizumab (Avastin).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the trial, the patients will receive single-agent tisotumab vedotin every three weeks.

The trial’s primary goal is objective response rate as assessed by independent review.

Its key secondary endpoints comprise duration of response, progression-free survival, overall survival, safety and tolerability.

“There remains a need for targeted agents that are effective for patients who progress or relapse after standard treatments.”

innovaTV 204 trial principal investigator Robert Coleman said: “While significant advances have been made in the treatment and prevention of cervical cancer, there remains a need for targeted agents that are effective for patients who progress or relapse after standard treatments.

“In a prior study, tisotumab vedotin demonstrated encouraging results in previously treated recurrent and/or metastatic cervical cancer, an area of unmet need where there is no established standard of care and response rates are limited.”

Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) currently being developed by Seattle Genetics along with Genmab.

It is designed to target Tissue Factor antigen on cancer cell surfaces and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells.

Seattle Genetics, in collaboration with Genmab, also plans to examine tisotumab vedotin in other solid tumours with unmet medical need for new treatment options.